Glaxosmithkline Plc Adr Stock Current Valuation
| GSK Stock | USD 33.96 0.26 0.77% |
Valuation analysis of GlaxoSmithKline PLC ADR helps investors to measure GlaxoSmithKline PLC's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The value of Enterprise Value Over EBITDA is expected to slide to 7.68. The value of Enterprise Value Multiple is estimated to slide to 7.68. Fundamental drivers impacting GlaxoSmithKline PLC's valuation include:
Price Book 3.9307 | Enterprise Value 85.1 B | Enterprise Value Ebitda 10.0816 | Price Sales 2.2129 | Forward PE 7.4571 |
Fairly Valued
Today
Please note that GlaxoSmithKline PLC's price fluctuation is very steady at this time. Calculation of the real value of GlaxoSmithKline PLC ADR is based on 3 months time horizon. Increasing GlaxoSmithKline PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
GlaxoSmithKline PLC's intrinsic value may or may not be the same as its current market price of 33.96, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 33.96 | Real 33.57 | Target 39.63 | Hype 33.58 | Naive 34.01 |
The intrinsic value of GlaxoSmithKline PLC's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence GlaxoSmithKline PLC's stock price.
Estimating the potential upside or downside of GlaxoSmithKline PLC ADR helps investors to forecast how GlaxoSmithKline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GlaxoSmithKline PLC more accurately as focusing exclusively on GlaxoSmithKline PLC's fundamentals will not take into account other important factors: GlaxoSmithKline PLC ADR Company Current Valuation Analysis
GlaxoSmithKline PLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current GlaxoSmithKline PLC Current Valuation | 85.07 B |
Most of GlaxoSmithKline PLC's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
GlaxoSmithKline Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for GlaxoSmithKline PLC is extremely important. It helps to project a fair market value of GlaxoSmithKline Stock properly, considering its historical fundamentals such as Current Valuation. Since GlaxoSmithKline PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlaxoSmithKline PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlaxoSmithKline PLC's interrelated accounts and indicators.
Click cells to compare fundamentals
GlaxoSmithKline Current Valuation Historical Pattern
Today, most investors in GlaxoSmithKline PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlaxoSmithKline PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of GlaxoSmithKline PLC current valuation as a starting point in their analysis.
GlaxoSmithKline PLC Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, GlaxoSmithKline PLC ADR has a Current Valuation of 85.07 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.
GlaxoSmithKline Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.GlaxoSmithKline PLC is currently under evaluation in current valuation category among its peers.
GlaxoSmithKline PLC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.Environmental | Governance | Social |
GlaxoSmithKline Fundamentals
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 85.07 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 15.38 % | ||||
| Number Of Shares Shorted | 16.29 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 3.93 X | ||||
| Price To Sales | 2.21 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 9.08 B | ||||
| Net Income | 4.93 B | ||||
| Cash And Equivalents | 3.72 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 18.02 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | 6.77 B | ||||
| Short Ratio | 3.29 X | ||||
| Earnings Per Share | 1.53 X | ||||
| Price To Earnings To Growth | 0.73 X | ||||
| Target Price | 45.95 | ||||
| Number Of Employees | 70.21 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 69.29 B | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.74 B | ||||
| Working Capital | (2.42 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 5.32 % | ||||
| Net Asset | 59.01 B | ||||
| Last Dividend Paid | 0.61 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.53 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.